Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
EBS [NYSE]
Emergent BioSolutions Inc.
Healthcare | Drug Manufacturers - Specialty & Generic | USA
statements
Index- P/E31.24 EPS (ttm)3.11 Insider Own2.70% Shs Outstand53.00M Perf Week-17.01%
Market Cap5.85B Forward P/E17.70 EPS next Y5.49 Insider Trans-15.66% Shs Float45.20M Perf Month-11.17%
Income166.60M PEG3.40 EPS next Q1.73 Inst Own87.10% Short Float5.30% Perf Quarter21.94%
Sales1.33B P/S4.39 EPS this Y-8.50% Inst Trans4.03% Short Ratio4.17 Perf Half Y-21.39%
Book/sh23.61 P/B4.11 EPS next Y-40.45% ROA7.00% Target Price113.00 Perf Year66.30%
Cash/sh6.89 P/C14.09 EPS next 5Y9.20% ROE14.80% 52W Range46.37 - 137.61 Perf YTD8.43%
Dividend- P/FCF30.15 EPS past 5Y-2.60% ROI4.80% 52W High-29.40% Beta1.20
Dividend %- Quick Ratio2.30 Sales past 5Y22.30% Gross Margin64.40% 52W Low109.51% ATR5.87
Employees1834 Current Ratio3.20 Sales Q/Q23.50% Oper. Margin19.70% RSI (14)37.57 Volatility5.57% 4.72%
OptionableYes Debt/Eq0.70 EPS Q/Q-11.90% Profit Margin12.80% Rel Volume0.89 Prev Close98.80
ShortableYes LT Debt/Eq0.68 EarningsFeb 18 AMC Payout0.00% Avg Volume573.98K Price97.15
Recom2.00 SMA20-14.59% SMA50-6.87% SMA200-0.58% Volume508,775 Change-1.67%
Feb-24-21Upgrade Chardan Capital Markets Neutral → Buy $112
Feb-19-21Downgrade Chardan Capital Markets Buy → Neutral $112
Jan-08-21Downgrade Wells Fargo Overweight → Equal Weight $110
Sep-14-20Resumed JP Morgan Neutral $103
Jul-31-20Reiterated Chardan Capital Markets Buy $86 → $112
Sep-12-19Initiated Guggenheim Buy
Sep-04-19Upgrade Wells Fargo Market Perform → Outperform
Nov-02-18Upgrade Goldman Neutral → Buy
Aug-03-18Reiterated Chardan Capital Markets Buy $53 → $57
Jun-13-18Initiated Argus Buy $62
Apr-25-18Downgrade Wells Fargo Outperform → Market Perform
Jan-24-18Initiated Goldman Neutral
Jan-16-18Reiterated Chardan Capital Markets Buy $47 → $53
Jun-28-16Reiterated Singular Research Buy $44 → $40
Apr-15-16Initiated Chardan Capital Markets Buy $47
Mar-28-16Initiated Singular Research Buy $44
Feb-19-16Initiated Wells Fargo Outperform
May-15-14Initiated Summer Street Research Buy $35
May-31-11Reiterated WBB Securities Strong Buy $20.50 → $30
Jan-10-11Reiterated Wedbush Outperform $27 → $32
Feb-25-21 07:00AM  
FOCUS-Wanted: More high-tech manufacturing space for a global vaccine push
Reuters
Feb-24-21 10:07AM  
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2021
Benzinga +5.68%
Feb-19-21 11:27AM  
Why Emergent BioSolutions Stock Is Sliding Today
Motley Fool -11.98%
10:57AM  
Looking Into Emergent BioSolutions's Return On Capital Employed
Benzinga
04:01AM  
Emergent BioSolutions Inc (EBS) Q4 2020 Earnings Call Transcript
Motley Fool
Feb-18-21 04:45PM  
Emergent BioSolutions: Q4 Earnings Insights
Benzinga
04:38PM  
Dow Jones Closes Lower After Jobless Claims Report; GameStop House Hearing Begins
Investor's Business Daily
04:25PM  
UPDATE 3-Vaccine manufacturing deals power Emergent BioSolutions profit beat
Reuters
04:05PM  
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2020
GlobeNewswire
03:15PM  
Emergent BioSolutions, Inc. to Host Earnings Call
ACCESSWIRE
Feb-17-21 12:44PM  
Co-Diagnostics Clears Technical Benchmark, Hitting 90-Plus RS Rating
Investor's Business Daily
Feb-15-21 12:00AM  
Shareholders Of Emergent BioSolutions (NYSE:EBS) Must Be Happy With Their 255% Total Return
Simply Wall St.
Feb-11-21 06:14AM  
3 Absurdly Cheap Coronavirus Stocks to Buy Now
Motley Fool
Feb-10-21 01:40PM  
Heat Biologics Stock Notches Scorching RS Rating
Investor's Business Daily
Feb-04-21 02:37PM  
IBD 50 Stocks To Watch: Emergent BioSolutions, A Biotech Stock With Solid Biodefense Cred
Investor's Business Daily
01:54PM  
Anavex Life Sciences Crp Earns 94 RS Rating; Soars To Record High
Investor's Business Daily
06:30AM  
Emergent BioSolutions to Release Fourth Quarter and Full Year 2020 Financial Results and Conduct a Conference Call on February 18, 2021
GlobeNewswire
Feb-03-21 12:08PM  
Is Emergent Biosolutions (EBS) Stock a Buy For 2021?
Insider Monkey
Feb-01-21 02:57PM  
Horizon Pharma Sees Rising Composite Rating To 96
Investor's Business Daily +8.37%
01:45PM  
Nasdaq Leads Market As Dow Jones Rises After Worst Week Since October; These Long-Term Leaders Near Buy Zones
Investor's Business Daily
Jan-27-21 01:06PM  
Stocks Showing Market Leadership: Sorrento Therapeutics Earns 93 RS Rating
Investor's Business Daily
12:45PM  
Emergent BioSolutions Getting Closer To Key Technical Benchmark
Investor's Business Daily
Jan-26-21 03:39PM  
Composite Rating For Pacira Pharmaceuticals Rises To 97
Investor's Business Daily
Jan-25-21 02:20PM  
IBD Rating Upgrades: Supernus Pharmaceuticals Flashes Improved Price Strength
Investor's Business Daily
01:21PM  
Humanigen signs manufacturing deal with Emergent for experimental COVID-19 drug
MarketWatch
08:30AM  
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab
Business Wire
Jan-20-21 12:45PM  
Top-Rated Stocks: Ligand Pharmaceuticals Sees Composite Rating Climb To 97
Investor's Business Daily
Jan-13-21 01:38PM  
Emergent BioSolutions Sees Its Composite Rating Rise To 97
Investor's Business Daily
Jan-12-21 10:37AM  
Emergent BioSolutions Is Looking Stronger
TheStreet.com
Jan-11-21 09:22AM  
Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View
Zacks
09:15AM  
How to Play Emergent BioSolutions Right Now
TheStreet.com
Jan-10-21 02:00PM  
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results
GlobeNewswire
Jan-07-21 12:45PM  
3 Reasons Why Growth Investors Shouldn't Overlook Emergent Biosolutions (EBS)
Zacks
Jan-06-21 05:50PM  
Emergent Biosolutions (EBS) Outpaces Stock Market Gains: What You Should Know
Zacks
11:30AM  
Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?
Zacks
Jan-05-21 07:03AM  
Is Emergent BioSolutions Stock a Buy?
Motley Fool
Jan-04-21 03:25PM  
England Goes Under National Lockdown
Barrons.com
06:30AM  
Emergent BioSolutions to Participate in Investor Conferences
GlobeNewswire
Dec-31-20 09:40AM  
Company News for Dec 31, 2020
Zacks
Dec-30-20 11:21AM  
Emergent BioSolutions Secures DOD Aid for Covid Treatment Test
TheStreet.com
Dec-29-20 04:05PM  
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis
GlobeNewswire
Dec-18-20 08:15PM  
Is EBS A Good Stock To Buy Now According To Hedge Funds?
Insider Monkey
Dec-17-20 09:19AM  
20 best mid-cap stocks for 2021, according to analysts
MarketWatch
Dec-16-20 11:56PM  
Is Now The Time To Put Emergent BioSolutions (NYSE:EBS) On Your Watchlist?
Simply Wall St.
Dec-15-20 09:38AM  
Emergent BioSolutions Inc. -- Moody's announces completion of a periodic review of ratings of Emergent Biosolutions Inc.
Moody's
Dec-05-20 11:32AM  
Emergent Biosolutions (EBS) Down 14.7% Since Last Earnings Report: Can It Rebound?
Zacks
Dec-02-20 12:35PM  
Is Emergent BioSolutions (EBS) a Smart Long-term Buy?
Insider Monkey
Nov-27-20 06:14AM  
3 Bargain Stocks You Can Buy Today
Motley Fool
Nov-18-20 09:30AM  
Is Emergent BioSolutions (EBS) a Good Stock to Pick Now?
Zacks -5.38%
Nov-10-20 09:40AM  
Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data
Zacks
Nov-09-20 10:18AM  
Deciphera (DCPH) Reports Narrower-Than-Expected Loss in Q3
Zacks
08:58AM  
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus
Zacks
Nov-06-20 06:50PM  
Why Emergent BioSolutions Slipped on Friday
Motley Fool
11:16AM  
Emergent (EBS) Beats on Q3 Earnings, Tapers '20 Sales View
Zacks
10:57AM  
BioMarin (BMRN) Beats on Q3 Earnings, Lowers Sales View
Zacks
10:54AM  
Global Blood (GBT) Q3 Loss Wider Than Expected, Sales Miss
Zacks
10:52AM  
Amicus' (FOLD) Q3 Loss Wider Than Expected, Revenues Beat
Zacks
10:51AM  
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates
Zacks
10:43AM  
Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact
Zacks
08:00AM  
Coronavirus Stocks Are Up Big This Year, But Which Ones Should You Buy?
Investor's Business Daily
Nov-05-20 07:40PM  
Emergent Biosolutions (EBS) Q3 Earnings Top Estimates
Zacks
04:05PM  
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance
GlobeNewswire
03:15PM  
Emergent BioSolutions, Inc. to Host Earnings Call
ACCESSWIRE
11:38AM  
Zoetis' (ZTS) Q3 Earnings and Revenues Surpass Estimates
Zacks
08:58AM  
Zoetis (ZTS) in Focus: Stock Moves 6.9% Higher
Zacks
Nov-04-20 09:52AM  
Allogene (ALLO) Q3 Earnings Top Estimates, Pipeline Progresses
Zacks +5.95%
Nov-03-20 10:29AM  
Apellis Pharmaceuticals' (APLS) Q3 Loss Wider Than Expected
Zacks
10:26AM  
Bayer's (BAYRY) Q3 Earnings & Sales Miss Estimates, Down Y/Y
Zacks
10:14AM  
Horizon (HZNP) Q3 Earnings Top Estimates, Tepezza Drives Sales
Zacks
09:36AM  
Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger
Zacks
Nov-02-20 12:46PM  
What's in Store for Emergent (EBS) This Earnings Season?
Zacks
11:06AM  
Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates
Zacks
Oct-30-20 03:54PM  
Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance
Zacks
Oct-29-20 05:45PM  
Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know
Zacks
02:25PM  
Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating
Investor's Business Daily
12:34PM  
Emergent Biosolutions (EBS) Earnings Expected to Grow: Should You Buy?
Zacks
11:24AM  
Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase
Zacks
Oct-28-20 10:32AM  
Ultragenyx (RARE) Loss Narrows Y/Y, Revenues Beat Estimates
Zacks
Oct-23-20 05:45PM  
Emergent Biosolutions (EBS) Stock Sinks As Market Gains: What You Should Know
Zacks
Oct-21-20 11:30AM  
Has Emergent Biosolutions (EBS) Outpaced Other Medical Stocks This Year?
Zacks
10:48AM  
Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II
Zacks
Oct-20-20 10:26AM  
Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients
Zacks
Oct-19-20 10:09AM  
Regeneron's (REGN) Dupixent Gets Positive CHMP Opinion for Dermatitis
Zacks
10:05AM  
ASLAN Pharmaceuticals (ASLN) in Focus: Stock Moves 7% Higher
Zacks
09:55AM  
Alnylam (ALNY) Gets Positive CHMP Opinion for Lumasiran
Zacks
Oct-16-20 09:58AM  
Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study
Zacks
08:54AM  
Anavex (AVXL) in Focus: Stock Moves 9.5% Higher
Zacks
Oct-15-20 05:45PM  
Emergent Biosolutions (EBS) Gains As Market Dips: What You Should Know
Zacks
12:45PM  
3 Reasons Growth Investors Will Love Emergent Biosolutions (EBS)
Zacks
10:24AM  
Bayer's Aliqopa Meets Primary Endpoint in Lymphoma Study
Zacks
Oct-14-20 10:03AM  
AnaptysBio Shares Up on Positive Top-Line Psoriasis Data
Zacks
Oct-13-20 12:31PM  
Why Emergent BioSciences Stock Is Falling Today
Motley Fool -13.64%
10:36AM  
Dow Jones Falls As These 2 Key Stocks Weigh, But Nasdaq Briefly Turns Higher
Investor's Business Daily
10:32AM  
Immunomedics' Trodelvy Gets Orphan Drug Tag for Glioblastoma
Zacks
10:30AM  
Alexion's Ultomiris Gets FDA Approval for New Formulation
Zacks
09:47AM  
Return On Capital Employed Overview: Emergent BioSolutions
Benzinga
09:45AM  
The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher
Zacks
08:30AM  
Aileron Therapeutics (ALRN) in Focus: Stock Moves 6.5% Higher
Zacks
Oct-12-20 09:45AM  
Booming Gene Editing Market to Pep Up These 5 Biotech Stocks
Zacks
08:50AM  
SpringWorks Therapeutics (SWTX) Surges: Stock Moves 9.6% Higher
Zacks
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kramer RobertPresident and CEOFeb 08Option Exercise30.7945,3971,397,961171,607Feb 09 05:23 PM
Kramer RobertPresident and CEOFeb 08Sale120.0345,3975,449,002139,210Feb 09 05:23 PM
Kramer RobertPresident and CEOJan 21Option Exercise26.4521,900579,255161,110Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 21Sale110.0321,9002,409,657139,210Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 20Option Exercise26.452,23259,036141,442Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 20Sale110.002,232245,520139,210Jan 22 04:14 PM
Kramer RobertPresident and CEOJan 15Option Exercise25.6219,026487,446158,236Jan 19 04:28 PM
Kramer RobertPresident and CEOJan 15Sale106.0119,0262,016,901139,210Jan 19 04:28 PM
El-Hibri FuadChairmanNov 10Option Exercise26.4519,391512,8921,143,379Nov 12 06:30 PM
El-Hibri FuadChairmanNov 10Sale88.2119,3911,710,4801,123,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 09Option Exercise26.4520,000529,0001,143,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 09Sale95.2620,0001,905,2001,123,988Nov 12 06:30 PM
El-Hibri FuadChairmanNov 03Option Exercise26.4520,000529,0001,143,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 03Sale90.7420,0001,814,8001,123,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 02Option Exercise26.4520,000529,0001,143,988Nov 04 08:53 PM
El-Hibri FuadChairmanNov 02Sale90.4420,0001,808,8001,123,988Nov 04 08:53 PM
El-Hibri FuadChairmanSep 24Sale98.8512,5351,239,0851,123,988Sep 25 07:00 PM
El-Hibri FuadChairmanSep 23Sale100.5813,0001,307,5401,136,523Sep 25 07:00 PM
El-Hibri FuadChairmanSep 17Sale100.6820,0002,013,6001,149,523Sep 18 06:25 PM
El-Hibri FuadChairmanSep 16Sale102.4820,0002,049,6001,169,523Sep 18 06:25 PM
El-Hibri FuadChairmanSep 10Sale102.6620,0002,053,2001,189,523Sep 11 09:21 PM
El-Hibri FuadChairmanSep 09Sale102.8020,0002,056,0001,209,523Sep 11 09:21 PM
SULLIVAN LOUIS WDirectorSep 02Option Exercise20.087,893158,49150,655Sep 04 08:08 PM
SULLIVAN LOUIS WDirectorSep 02Sale111.2228,4183,160,60642,762Sep 04 08:08 PM
Bailey SueDirectorAug 18Sale128.314,665598,56432,595Aug 19 05:08 PM
Harsanyi ZsoltDirectorAug 17Sale133.716,609883,66424,579Aug 18 09:12 AM
JOULWAN GEORGE ADirectorAug 11Sale124.116,000744,63526,771Aug 12 04:52 PM
Zoon Kathryn CDirectorAug 10Sale130.271,000130,27012,489Aug 11 04:43 PM
Richard RonaldDirectorAug 07Sale131.006,297824,9078,276Aug 11 04:46 PM
Richard RonaldDirectorJun 03Sale87.516,572575,1424,269Jun 05 04:36 PM
Bailey SueDirectorJun 03Sale87.505,322465,69137,260Jun 05 04:33 PM
Hauer Jerome MDirectorMay 26Sale85.154,385373,37310,188May 27 05:10 PM
Zoon Kathryn CDirectorMay 26Sale85.104,093348,32213,489May 27 05:07 PM
Harsanyi ZsoltDirectorMay 14Option Exercise18.643,43464,01028,367May 18 07:12 PM
Zoon Kathryn CDirectorMay 12Sale85.211,660141,45414,761May 14 04:30 PM
Harsanyi ZsoltDirectorMay 11Sale81.994,940405,02524,933May 13 07:47 PM
JOULWAN GEORGE ADirectorMay 11Sale85.192,000170,37129,950May 13 07:45 PM
Richard RonaldDirectorMay 05Sale80.198,375671,6298,020May 06 05:08 PM
El-Hibri FuadChairmanApr 30Sale74.0120,0001,480,2001,229,523May 01 08:13 PM
El-Hibri FuadChairmanApr 29Sale74.2420,0001,484,8001,249,523May 01 08:13 PM
Richard RonaldDirectorApr 27Option Exercise20.087,893158,49124,288Apr 29 04:35 PM
Richard RonaldDirectorApr 27Sale78.007,893615,65416,395Apr 29 04:35 PM
El-Hibri FuadChairmanApr 23Sale68.4920,0001,369,8001,269,523Apr 24 04:16 PM
El-Hibri FuadChairmanApr 22Sale66.8120,0001,336,2001,289,523Apr 24 04:16 PM
Havey AdamEVP, Business OperationsApr 20Option Exercise30.8617,009524,89851,265Apr 21 06:12 PM
Havey AdamEVP, Business OperationsApr 20Sale69.0017,0091,173,62134,256Apr 21 06:12 PM
Havey AdamEVP, Business OperationsApr 17Option Exercise26.4520,414539,95054,670Apr 21 06:12 PM
Havey AdamEVP, Business OperationsApr 17Sale65.0020,4141,326,91034,256Apr 21 06:12 PM
El-Hibri FuadChairmanApr 16Sale62.4720,0001,249,4001,309,523Apr 20 06:30 PM
El-Hibri FuadChairmanApr 15Sale62.5812,537784,5651,329,523Apr 15 09:04 PM
El-Hibri FuadChairmanApr 14Sale62.996,261394,3801,342,060Apr 15 09:04 PM
El-Hibri FuadChairmanApr 13Sale62.2517,0711,062,6701,348,321Apr 15 09:04 PM
El-Hibri FuadChairmanApr 09Sale61.8323,7161,466,3601,365,392Apr 10 07:13 PM
El-Hibri FuadChairmanApr 08Sale61.1337,3622,284,1151,389,108Apr 10 07:13 PM
El-Hibri FuadChairmanApr 07Sale60.7614,336871,0551,426,470Apr 08 09:17 PM
Kirk SeanEVP, Manufacturing & Tech OpsApr 06Option Exercise30.7010,428320,13119,864Apr 08 08:19 PM
El-Hibri FuadChairmanApr 06Sale60.5028,2401,708,5201,440,806Apr 08 09:17 PM
Havey AdamEVP, Business OperationsApr 06Sale60.007,972478,32034,256Apr 08 08:22 PM
Kirk SeanEVP, Manufacturing & Tech OpsApr 06Sale60.0016,094965,64012,571Apr 08 08:19 PM
Harsanyi ZsoltDirectorMar 16Sale65.006,400416,00029,873Mar 17 04:39 PM
SULLIVAN LOUIS WDirectorMar 04Option Exercise13.8615,786218,71568,359Mar 06 04:37 PM
Zoon Kathryn CDirectorMar 04Sale60.6599160,10316,421Mar 06 04:39 PM
SULLIVAN LOUIS WDirectorMar 04Sale58.9615,786930,71460,466Mar 06 04:37 PM
El-Hibri FuadChairmanFeb 27Sale56.979,837560,4141,469,046Feb 28 08:01 PM
Bailey SueDirectorFeb 27Sale56.936,572374,13239,761Mar 02 05:28 PM
open in yahoo | open in reuters | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.